More on REGN
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $764.93 |
|
|||
| Open | $755.01 | ||||
| 52 Wk High | $592.36 | ||||
| 52 Wk Low | $325.35 | ||||
| Day High | $762.40 | ||||
| Day Low | $746.66 | ||||
| P/E | 199.44 | ||||
| EPS | $3.81 | ||||
| Volume | 561,909 | ||||
- Barclays Starts Regeneron Pharma (REGN) at Overweight
- Regeneron Announces Investor Conference Presentation
- Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsight
- Form 4 REGENERON PHARMACEUTICAL For: Mar 02 Filed by: RYAN ARTHUR F
- Regeneron Pharma (REGN) PT Raised to $765 at RBC Capital
- Dupixent gets European panel backing for young children with chronic hives
- Dupixent® (dupilumab) Recommended for EU Approval to Treat Chronic Spontaneous Urticaria (CSU) in Young Children with Ongoing Symptoms Despite Treatment
- Regeneron Renews Sponsorship of the Regeneron Science Talent Search Through 2036, Committing an Additional $150 Million to Empower the Next Generation of Science and Technology Leaders
- Regeneron Pharma (REGN) PT Lowered to $180 at Wells Fargo
- Regeneron Pharma (REGN) PT Lowered to $152 at Jefferies
Entities mentioned with REGN
- FDA | View Related Stories »
- Twitter | View Related Stories »
- Earnings | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Genzyme/Sanofi-Aventis | View Related Stories »
- Definitive Agreement | View Related Stories »
- Show More...
